Compare CMCM & RFL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CMCM | RFL |
|---|---|---|
| Founded | 2009 | 2017 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Real Estate |
| Sector | Technology | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 93.4M | 92.6M |
| IPO Year | 2014 | 2017 |
| Metric | CMCM | RFL |
|---|---|---|
| Price | $3.14 | $2.25 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 26.5K | ★ 364.7K |
| Earning Date | 06-18-2026 | 06-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 28.28 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $917,000.00 |
| Revenue This Year | $11.61 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 43.96 |
| 52 Week Low | $2.65 | $1.12 |
| 52 Week High | $9.44 | $3.96 |
| Indicator | CMCM | RFL |
|---|---|---|
| Relative Strength Index (RSI) | 33.54 | 46.75 |
| Support Level | $2.65 | $1.21 |
| Resistance Level | $7.09 | $3.96 |
| Average True Range (ATR) | 0.23 | 0.38 |
| MACD | 0.04 | -0.13 |
| Stochastic Oscillator | 39.60 | 4.42 |
Cheetah Mobile Inc along with its subsidiaries provides comprehensive products and services on PCs and mobile devices. It generates revenue from utility-related business, including advertising services and premium membership services. It also provides multi-cloud management platform and overseas advertising agency service. The company operates in two segments: Internet business, and AI and others. The companies products and services includes Robotic Products, Global to B Services etc. The firm's majority of the revenue is derived from the internet business segment that provides mobile advertising services to advertising customers, as well as selling advertisements and referring user traffic on its mobile and PC platforms. Geographically, it derives the majority of its revenue from the PRC.
Rafael Holdings Inc is a biotechnology firm that develops pharmaceuticals and invests in clinical and early-stage companies in pharmaceuticals and medical devices. Trappsol Cyclo is in Phase 3 trials for Niemann-Pick Disease Type C1. The company focuses on completing these trials, seeking regulatory approval, and commercializing the product. It also invests in portfolio companies including Cyclo, LipoMedix, Barer, Rafael Medical Devices, Cornerstone, and Day Three, targeting therapeutics for unmet medical needs. The business operates through three segments: Healthcare, Infusion Technology, and Real Estate. Operations are based in the United States and Israel.